On 22nd April, 2020, the European Commission approved Malta's €5.3 million scheme to support investment in research and development related to the current pandemic.
Any company, including public entities, intending to undertake research and development regarding COVID-19, and other related projects may benefit under the scheme. The scheme is intended to support the development of new solutions – such as medicinal products, medical equipment, and data collection tools – for the current crisis while also bettering foresight tools and methodologies for the future.
Beneficiaries will receive aid, in the form of direct grants, of between 80% and 100% of the costs incurred by the beneficiary, depending on the costs incurred by them. The results achieved through such research and development will be shared among countries of the European Economic Area through non-exclusive licences.
In approving the scheme, the European Commission found it in line with the conditions laid out in the State Aid Temporary Framework, which was adopted on 19th March, 2020 and subsequently amended on 3rd April, 2020.
Originally published by MAMOTCV, April 2020
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.